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Questing for an optimal, universal viral agent for oncolytic virotherapy
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One of the most promising strategies to treat cancer is attacking it with viruses designed to ex-
ploit specific altered pathways. Here, the effects of oncolytic virotherapy on tumors having compact,
papillary and disconnected morphologies are investigated through computer simulations of a mul-
tiscale model coupling macroscopic reaction diffusion equations for the nutrients with microscopic
stochastic rules for the actions of individual cells and viruses. The interaction among viruses and
tumor cells involves cell infection, intracellular virus replication and release of new viruses in the
tissue after cell lysis. The evolution in time of both viral load and cancer cell population, as well
as the probabilities for tumor eradication were evaluated for a range of multiplicities of infection,
viral entries and burst sizes. It was found that in immunosuppressed hosts, the antitumor efficacy
of a virus is primarily determined by its entry efficiency, its replicative capacity within the tumor,
and its ability to spread over the tissue. However, the optimal traits for oncolytic viruses depends
critically on the tumor growth dynamics and do not necessarily include rapid replication, cytolysis
and spreading currently assumed as necessary conditions to a successful therapeutic outcome. Our
findings have potential implications on the design of new vectors for the viral therapy of cancer.
PACS numbers: 87.19.xj, 87.10.Mn, 87.18.Hf
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I. INTRODUCTION
Despite the progress that has been made in imag-
ing, diagnosis, treatment and understanding of cancer,
the survival rates of patients with metastatic or recur-
rent neoplasias as well as patients with tumors at un-
resectable locations are still poor, and new therapeutic
strategies are needed [1]. Furthermore, occult dormant
micrometastasis raise new challenges concerning their re-
activation and evolution into clinically manifested dis-
ease, particularly after primary tumor resection [2].
Oncolytic virotherapy is claimed to be a promising
anti-cancer strategy, because it can provide a locoregional
control or even eradication of tumors without cross-
resistance with standard therapies. Oncolytic viruses are
able to selectively infect and kill tumor cells by exploit-
ing the same cellular defects that promote tumor growth
[3]. To date, several different viruses are known to be
selectively oncolytic [4]. An archetype is the adenovirus
commonly used in gene therapy and oncolytic therapy
experiments [5, 6]. Some studies indicate that the virus
effectiveness strongly depends on the specific cancer cell
line [1]. So, one can hypothesize that for each tumor
there must exist an oncolytic virus that maximizes the
therapeutic success.
Several mathematical models have been proposed to
study virotherapy [7–10]. They emerge as valuable tools
to provide quantitative understanding of the major mech-
anisms that affect anti-cancer treatment based on viruses
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and to select parameter ranges that enhance its therapeu-
tic success. Specially because, in face of the nonlinear-
ities and complexity involved in cancer progression and
its interaction with oncolytic viruses, intuitive reason-
ing alone may be insufficient. The current paradigm is
that the viral life cycle should lead to rapid replication,
cytolysis and spread [11]. Nonetheless, the limitations
and validity of this appealing, intuitive, and seemingly
logical paradigm remains unclear. Indeed, at least one
mathematical result [8] indicates that viruses able to de-
stroy tumor cells very fast does not necessarily lead to a
more effective control of tumor growth. More precisely,
it was shown that a successful virotherapy of compact
tumors requires both highly spreading viruses and an op-
timal range of viral cytotoxity, i. e, neither a too short
nor a very large time for the lysis of cancer cells. How-
ever, this result was derived assuming that the viruses
are a continuous field whose dynamics is described by a
reaction-diffusion equation. Furthermore, the changes in
the stationary local concentrations of viruses due to their
entry at cell infections were neglected and the viral burst
size used, equal to the initial viral load, was orders of
magnitude greater than the larger ones observed for real
oncolytic viruses.
In the present paper, a multiscale model based on the
approach proposed by Ferreira et al. [12] was modified
to take explicitly into account the individual, discrete
nature of the oncolytic viruses and applied to evaluate
the efficacy of virotherapy against compact, papillary and
diffuse (disconnected) solid tumors. Considering virus
as discrete agents provides a more realistic description
of virus entry and replication, key processes involved in
oncolytic virotherapy. Our main goal is provide useful
insights about how to match the oncolytic virus and the
tumor type in order to get the better outcome for the
therapy.
2II. MODEL
Figure 1 illustrates the multiple agents and processes
involved in the model at distinct time and length scales.
The tissue is modelled by a square lattice fed through a
single capillary vessel at its top. Four different cell types
(normal and dead cells, uninfected and infected tumor
cells) and an oncolytic virus are considered. These indi-
vidual agents are described by their populations σn, σd,
σc, and σv, respectively, at every site x. In contrast to
the normal and dead cells, one or more uninfected or in-
fected cancer cells can pile up in a given site, reflecting
the fact that the division of tumor cells is not constrained
by contact inhibition. In turn, since the viruses are very
small particles in comparison with cells, there is no con-
straint on their population.
The nutrients, diffusing from the capillary vessel
throughout the tissue, are divided into two groups: those
that limits cell replication but are not demanded for cell
survival (j = 1) and those essential to maintain the basic
cell functions and whose deprivation can induce death
(j = 2). Both nutrient types are described by contin-
uous fields φj(~x, t), which evolve in space and time ac-
cording the simplest (linear with constant coefficients)
dimensionless reaction-diffusion equations
∂φj
∂t
= ∇2φj − α
2φjσn − λjα
2φjσc. (1)
The factors λj take into account distinct nutrient uptake
rates for normal and cancer cells. The parameter α sets
up a characteristic length scale for nutrient diffusion in
the normal tissue (see reference [13] for the complete vari-
able transformations leading to this dimensionless equa-
tion). Eq. (1) obeys a periodic boundary condition along
the direction parallel to the capillary and a Neumann
boundary condition at the border of the tissue. At the
capillary vessel the nutrient concentrations are φj = 1
(continuous and fixed supply).
Each uninfected cancer cell, randomly selected with
equal probability, can carry out one of four actions:
1-Mitotic replication, with a probability
Pdiv = 1− exp
[
−
(
φ1
θdivσc
)2]
, (2)
an increasing function of the concentration per cancer cell
of the nutrients φ1. The daughter cell randomly occupies
one of their normal or necrotic nearest neighbor sites,
whether there exists any, or piles up at its mother site.
In the simulations, we observed at most three or four
cancer cells at the same site simultaneously.
2-Death, with a probability
Pdel = exp
[
−
(
φ2
θdelσc
)2]
, (3)
that increases with the scarcity of nutrients φ2 essential
to sustain the cell metabolism.
3-Migration, with a probability
Pmov = 1− exp
[
−σc
(
φ2
θmov
)2]
, (4)
that increases with the local population of cancer cells
and the nutrient concentration per cell. A probability
increasing with the nutrient concentration is justified by
the necessity of nutrients for cell motility and, in ad-
dition, by the degradation of the extracellular matrix
nearby the tumor surface that releases several chemicals
which promote cell migration and proliferation. This hy-
pothesis is consistent with experimental data in multi-
cellular tumor spheroids [14] and was previously used in
other mathematical models [15, 16]. The migrating cell
moves to one of its nearest-neighbor sites chosen at ran-
dom, interchanging its position with a normal or necrotic
cell if there exists any. If the interchanged normal or
necrotic cell moved to a site still occupied by other can-
cer cells, it is eliminated. These rules for cancer growth
are similar to those used by Scalerandi et al. [17] in a
deterministic model with collective cell actions controlled
by threshold (step) functions of the nutrient concentra-
tion per cancer cell.
4-Become infected with a probability
Pinf = 1− exp
[
−
(
σv
σcθinf
)2]
, (5)
an increasing function of the local viral load per cell,
controlled by the parameter θinf . The model assumes
perfect viral selectivity for cancer cells, thereby the in-
fection of normal cells by oncolytic viruses is neglected.
The number of viruses nv that infect a given cell is se-
lected from a Poisson distribution,
P (nv) =
knve−k
nv!
, (6)
where k is the typical viral entry. This Poisson law has
been observed in cell cultures as a function of the mul-
tiplicity of infection (MOI), defined as the ratio between
the total viral load injected in the system and the num-
ber of target cells [18]. The model assumes that an in-
fected cancer cell does not divide nor migrate because its
slaved cellular machinery is focused on virus replication.
It is also assumed that infected cancer cells sustain their
metabolism until lysis and die only by lysis. The death
by lysis occurs with a probability
Plysis = 1− exp
(
−
Tinf
Tl
)
, (7)
3where Tinf is the time elapsed since the cell infection
and Tl is the characteristic time for cell lysis. The lysis
of each infected cancer cell releases
v0 = bs
nv
A+ nv
(8)
free viruses to the extra-cellular medium. Here, the max-
imum virus burst size bs and A are model parameters. At
the time of lysis, the new free viruses remains on the site
of the lysed cell. They diffuse independently through the
tissue by performing lattice random walks comprising q
steps and are cleared at a rate γv at each time step. The
clearance rate γv embodies the complex innate and adap-
tive immune responses to a virus. Such response involves
the synthesis of antiviral cytokines, activation/selection
of immune cells, and production of antiviral antibodies
[19].
The tumor starts to grow from a single cancer cell and
the therapy begins when the tumor attains N0 cells. It
consists of a single direct intratumoral administration in
which N0 ×MOI viruses are uniformly spread over the
entire tumor. This approach corresponds to the experi-
mental protocols used in severe combined immune defi-
cient (SCID) mice [20] and in vitro assays [21, 22]. In-
deed, in most of the in vivo virotherapy experiments the
virus are injected directly into a subcutaneous, avascular
tumor developed in mice.
More details concerning the procedures used for model
simulations are provided in appendices A and B.
III. RESULTS
We are interested on the effects of virotherapy on
compact, papillary and disconnected tumors, the gen-
eral morphologies observed in solid malignant neoplasias.
Typical patterns corresponding to such morphologies
were simulated using the multiscale model for the growth
of avascular tumors studied in reference [13]. They are
shown in Figure 2 and the model parameters used are
listed in Table 1.
Typical progress curves for cancer cells and free viruses
in a simulated virotherapy of a diffuse tumor are shown
in Figure 3. Similar time evolutions are also observed
for solid and papillary neoplastic morphologies (see Ap-
pendix C). Two regimes are observed: either the cancer
cell population keeps growing after the virus administra-
tion or both cancer cells and oncolytic viruses are erad-
icated. In the former regime, in which the virotherapy
fails, the viruses can be either eradicated or coexist with
the tumor cells. Such coexistence can exhibit oscillations
in cancer cells and virus populations due to successive
rounds of infection unable to eliminate the tumor. As
previously reported [8], it is worth to emphasize that any
of these behaviors can randomly emerge as the response
of a given tumor to the virotherapy. Hence, it becomes
imperative to determine for each tumor morphology the
most probable prognosis after the treatment as well as the
chances for the occurrence of the other tumor responses
as functions of the virotherapeutic parameters.
The probabilities for the eradication of a papillary tu-
mor are shown in Figure 4. As one can see, a sin-
gle intratumoral administration of an aggressive virus
(θinf = 0.01) at a MOI = 1.0 with viral entry k = 1.0,
low clearance rate γv = 0.03 and N0 = 10, 000 can erad-
icate the tumor. Even viruses with low replicative po-
tential, associated to small burst sizes (bs = 10, for in-
stance), have almost 100% of efficacy if they spread very
slowly (q <∼ 4) throughout the papillary tumor. As shown
in Figure 4(a), the anti-tumor efficacy of low-diffusive
viruses depends very weakly on Tl, the characteristic time
spent by the virus to induce the lysis of infected can-
cer cells. Furthermore, the anti-tumor efficacy decreases
rapidly with the increase of the virus diffusivity, almost
vanishing for q >∼ 9. In contrast, for a highly replica-
tive virus (burst size bs = 100), the tumor eradication is
almost always certain. The exceptions are for highly cy-
tolytic (Tl <∼ 10) and diffusive (q
>
∼ 20) viruses. Indeed,
as shown in Figure 4(b), the probability of therapeutic
success goes to zero if the oncolytic virus spreads very
fast on the tissue and quickly kills cancer cells.
Bearing in mind the current paradigm (fastest viral
replication, cytolysis and spreading), the correlations re-
vealed here among therapeutic outcomes and the traits
of the anti-tumor vectors figure out a counter intuitive
scenario. Indeed, a low viral diffusivity, independently
on the cytolytic period Tl and replicative capacity bs,
is sufficient because papillary malignant neoplasias grow
slowly. Nonetheless, one can argue that virus exhibiting
low diffusion rates in tissues will hardly reach the tumor
if intravenously or systemically administered. Hence this
trait should be clinically avoided unless delivery barriers
have been overcame through some “pro-diffusive” strat-
egy. As an alternative, our results indicate that fast
spreading viruses combining high replication potentials
and slow citolysis can successfully eliminate papillary tu-
mors.
The aforementioned results should be confronted with
those obtained for a compact tumor in order to deter-
mine if the most effective virus against papillary tu-
mors is equally efficient in the treatment of a compact
tumor. Compact morphologies are generated in our
model when competition for nutrients is weak and, conse-
quently, the tumor grows fast. The same oncolytic virus
and treatment protocol successfully used for papillary tu-
mors (γv = 0.03, θinf = 0.01, MOI = 1, k = 1 and
N0 = 10, 000) fails for compact tumors. They are not
eradicated for any Tl and q values studied even for a large
burst size (bs = 100). So, very efficient viruses against
papillary tumors can be ineffective to eradicate compact
tumors. While the number of cancer cells increases, the
viruses either become extinct, if q = 1, or coexist with
the growing tumor, if q > 1. In the coexistence regime,
the tumor grows continuously but at a lower rate.
Given that solid tumors grow faster than ramified
4ones, it seems intuitive to assume that more diffusive
viruses might be more effective against the neoplastic
mass. However, the success probabilities remain null if
only the viral diffusivity is increased up to values so large
as q = 900. One alternative towards a successful therapy
is reinforce the viral load initially administered. Nonethe-
less, even at larger MOIs (MOI = 5, for instance) the
therapy still completely fails if the viral entry k = 1 is
maintained. The value k = 1 implies that in average only
one virus invades a cell at each infection event.
A remaining strategy to control compact tumor growth
is enhance the viral entry. As one can see in figure 5(a),
a large viral entry (k = 5) has a dramatic effect on the
therapeutic success. Indeed, the virotherapy only fails,
even using a MOI = 1, for very low viral diffusivity
(q ≤ 2) and large lytic period (Tl >∼ 15). Furthermore,
a significant success is achieved by reducing k while, in
balance, raising the MOI used. This is shown in figure
5(b) in which k = 1.5 and MOI = 1.5. In this case, a
successful therapy demands an oncolytic virus with ap-
propriated diffusivity and lytic cycle. An adequate diffu-
sion (3 <∼ q
<
∼ 16) allows viral spreading throughout the
compact tumor at a rate similar or greater than that of
the growing neoplasia. But fixed the viral diffusivity, the
time Tl must lie within a certain range, as for instance
7 <∼ Tl ≤ 32 for q = 15. Indeed, a very rapid cytolysis
promptly forms “voids” containing the majority of the
newly released viruses, which impair the generation of
new infection waves. In turn, a very long Tl generates
successive waves of infection at a low frequency unable
to destroy the tumor. These results are consistent with
those reported on reference [8], supporting the robustness
of both models.
At last, the response of diffuse tumors to virotherapy
was investigated. In our model those disconnected pat-
terns emerge for highly motile cells that uptake nutrients
at moderate rates. Considering an oncolytic virother-
apy based on a viral agent with high replicative capacity,
the probability for the eradication of a diffuse tumor is
shown in Figure 6. As one can see, the success probabil-
ity also vanishes for highly diffusive viruses and increases
significantly for viruses spreading slowly. Optimal on-
colytic viruses for treat diffuse tumors should combine
high replicative rates and intermediate diffusivity. If the
virus has a slower spreading, then a short time for in-
duce the lysis of infected cancer cells is demanded in or-
der to maximize the therapeutic success. At larger viral
spreading (8 <∼ q
<
∼ 16) the success probability exhibit a
re-entrant behavior characterized by an initial decrease,
followed by an increase of the therapeutic success as the
cytolytic period Tl increases.
IV. DISCUSSION
In this work we investigated the oncolytic virothera-
peutic outcomes for solid (compact, papillary and dif-
fuse) tumors using numerical simulations. We focussed
our study on vectors with high infectivities and small
clearance rates corresponding to a severe suppression of
the host immune response. Furthermore, since in the
present framework the discrete nature of the oncolytic
virus allows a more realistic modeling of viral infection
and replication processes, the central roles of viral burst
size bs, virus entry k and initial MOI for the therapeutic
success are highlighted.
Figure 3 illustrates our typical results: after a single
intratumoral virus administration, these tumors can ei-
ther be completely eradicated or keep growing with time
despite a transient remission, as previously obtained for
compact tumors [8]. Furthermore, the last behavior can
be either a monotonic or an oscillating growth. It is
worthy to notice that such oscillations were observed in
human myeloma xenografts induced in mice treated with
measles virus (MV) [23], in an ovarian cancer xenograft
model [24], and in a mathematical approach used by
Dingli et al. for modeling MV virotherapy [25]. The
therapeutic outcome depends on both viral characteris-
tics and tumor dynamics. So, for fixed viral infectivity
θinf and persistence within the tissue determined by γv,
the key parameters that control treatment success are the
virus entry k, viral diffusivity q, characteristic lytic time
Tl and tumor growth rates.
Concerning the virotherapy of solid tumors, two main
results deserve special attention. Firstly, in the case of
a low virus entry (k = 1) successful therapeutic out-
comes were observed only at large, but realistic, initial
MOIs and viral burst sizes. It must be mentioned that
the viral burst size used in reference [8], equal to the
initial viral load, was one order of magnitude greater
than the larger viral burst sizes observed for real on-
colytic viruses. In turn, the large initial MOIs required by
successful virotherapies in our present simulations with
k = 1 raises the question of the clinical risks involved.
Viral doses ranging from about 107 pfu (MOI ≈ 0.08) to
109 pfu (MOI ≈ 8) were used in experimental tests [26].
Also, it is known that the oncolytic adenovirus dl1520
(or ONYX-015) is well tolerated at the higher practi-
cal administered doses (2× 1012—2× 1013 particles) [6].
But at very high viral titer (about 1 × 1014 particle per
Kg) this virus caused the death of a gene therapy pa-
tient with ornithine-cystosine transferase deficiency [27].
Hence, the use of reduced viral doses is pursued in clinical
applications, particularly in order to allow for systemic
administration.
Successful outcomes could be accomplished by raising
the viral entry k (see figure 5). Indeed, k represents the
average number of virus entering in a cancer cell at infec-
tion. Thus, large values of k result in a high production
of new viruses (v0 ∼ bs, the viral burst size) that are re-
leased after cell lysis. This local enhancement of the free
virus load enlarges, in turn, the probability of further
cancer cell infection. The consequence of such a positive
feedback cycle is that the initial viral load is sufficient
to trigger a powerful first wave of infection, whose suc-
cessive rounds ends to destroy the tumor. Moreover, as
5shown in figure 5(b), a relatively slight and simultane-
ous increase of both virus entry andMOI can be enough
to guarantee a successful oncolytic treatment of compact
tumors with safe viral doses.
Secondly, considering that large viral loads involve
risks and that an elevated virus entry may represent a
significant technical barrier, treatments based on inter-
mediate MOIs and k values become of special interest.
In this range (MOI ∼ 1 and 1 ≤ k < 2), the key factors
determining the therapeutic success are viral diffusivity
and cytolytic period. The probability of tumor eradica-
tion vanishes for viruses that diffuse very fast even at
large MOIs. Indeed, a very rapid spreading disperses the
viruses outside the growing tumor where they can not
trigger new waves of infection. In turn, since the growth
of compact tumors is faster, an effective oncolytic virus
must not diffuse slower than the tumor spreading. At in-
termediate values of k and MOI, in addition to be able
to spread at a rate similar to that of the growing tumor,
the virus must induce the lysis of infected cancer cells
neither too slowly nor too fast. If the time Tl for cy-
tolysis is very short, “voids” containing the majority of
the new released viruses are rapidly formed throughout
the tumor. These viruses can not trigger new infection
waves and cancer cells at the border of some voids es-
cape. In turn, if Tl is very long, the successive waves
of infection are generated at a low frequency, excessively
distant in time to destroy the tumor. These findings are
consistent with the predictions in Figure 5 of reference
[8] which suggests that the ideal oncolytic virus should
have neither a very short nor a long lytic cycle.
Summarizing, a successful virotherapy of compact tu-
mors demands the simultaneous optimization of several
factors: the use of oncolytic viruses with high replica-
tive capacities (burst sizes), adequate diffusivities (rapid
but not too rapid spreading) and lytic cycle (neither too
short nor too long), as well as a large initial viral en-
try. The importance of the initial MOI, strongly em-
phasized by Demers et al. [28] and Myers et al. [23],
is much smaller than that associated to the virus entry.
In those experiments, huge variations in the initial viral
load, from 104 to 1010 viral particles, were performed.
Such values correspond to MOIs ranging from around
0.5 to about 500. As one can intuitively expect, our sim-
ulations evidence that a huge MOI eradicate the tumor
independently of other factors (viral traits and tumor
growth dynamics). However, for virotherapies based on
low virus entries andMOIs there is, fixed the viral diffu-
sivity, an optimal range for its lytic cycle period because
the virotherapy fails if the cytolysis is either too short or
too long. This result is in complete agreement with the
findings of Paiva et al. [8]. Furthermore, we point out
that the virotherapeutic efficacy is much more sensitive
to other parameters, for instance viral entry and burst
size, than to MOI.
With regard to papillary tumors, a virotherapy based
on small virus entry (k = 1) and initial viral load
(MOI = 1) can control cancer growth. In this case the
key factors determining a successful therapeutic outcome
are the virus spreading and its replicative ability. In-
deed, for small viral burst sizes the therapeutic outcome
for papillary tumors is almost independent on Tl. We
find that the virotherapy fails for oncolytic viruses with
high diffusivity. Success probabilities greater than 70%
are observed only for very small diffusivities (q <∼ 6). In
contrast, for a fixed diffusivity, the therapeutic success of
highly replicative viruses exhibits a re-entrant behavior
as a function of their lytic periods, as shown in Figure
4(b). Again, our simulations suggest an optimal range
for the time Tl demanded by the oncolytic virus to kill
an infected tumor cell.
At last, for fixed small virus entry (k = 1) and ini-
tial viral load (MOI = 1), optimal oncolytic viruses for
treat diffuse tumors should exhibit high replicative rates
and intermediate diffusivity. For faster viral spreading
(q >∼ 8), a successful therapeutic outcome has a complex
dependence on Tl. A re-entrant behavior is observed,
leading to a decreasing success probability at an interme-
diate range of the time Tl for cytolysis. In contrast, for
oncolytic viruses having very slower spreadings, highly
successful therapies demanded short times for induce the
lysis of infected cancer cells.
A relevant issue is how our simulation results can be
compared with those obtained from experimental assays
or clinical trials on oncolytic virotherapy. Unfortunately,
this represents a difficult task due to the scarcity of quan-
titative experimental data. Most of the studies on on-
colytic virotherapy focused primarily on the safety of
these vectors and evaluate the anti-cancer efficacy of
viruses. Tests in vitro involves cancer cells cultured in
monolayer or 3d compact tumor spheroid models. Either
the xenograft models in experimental animals or the hu-
man tumors treated in clinical trials are also solid tu-
mors with compact morphologies. Furthermore, since
very distinct tumors were treated using several differ-
ent viruses, both the system and the therapeutic condi-
tions varied widely. Hence, almost all parameters have
changed simultaneously from one experiment to another.
Basically, the results are qualitative: the anti-tumor ef-
ficacy of viruses has been limited. Virotherapy is im-
paired by multiple factors, specially the low viral loads
and its suboptimal delivery to the target site, barriers to
viruses spreading within the tumor and the host immune
response against these vectors.
Our simulations reveal that the virus entry k is the
major parameter determining the therapeutic outcome.
Once its value is fixed, the lower is the initial dose of virus
administered, smaller is the chance of tumor eradication.
Experimental [23] and mathematical [25] results support
this direct correlation between MOI and therapeutic suc-
cess. Also, our simulations indicate that virus replication
within the tumor tissue, modelled by the viral burst size
bs, is the next main trait in the hierarchy of factors de-
termining the virotherapeutic success. Such finding is
supported by observations from Friedman et al. [7]. De-
creasing in the hierarchy, the viral diffusivity emerges as
6the next key parameter for a successful virotherapy. Ex-
perimental observations reporting that antitumor efficacy
increases as intratumoral virus spreading is enhanced due
to voids and channels generated by induced cancer cell
apoptosis inside a tumor [29] are in agreement with this
result. Finally, experimental data that confront our re-
sults concerning the effects of the cytolytic time on the
therapeutic outcome are lacking.
From our model simulations the efficiency of virus en-
try in a cell, its replicative capacity inside an infected
cell, and its diffusivity within the tumor tissue emerges
as three crucial factors to fuel and amplify the succes-
sive rounds of infection necessary to control or eradicate
the tumor. Hence, it is worthy to briefly comment about
some trends on the experimental research in these di-
rections. Concerning virus entry, a major challenge is
the engineering of entry proteins to achieve higher in-
fectivity. But this approach is diametrically opposite to
the search for entry inhibitors, neutralizing antibodies
and vaccine immunogens that elicit antibodies against
virus entry proteins [30, 31]. Instead of fight virus, the
goal is transform it into a better entry machine while re-
inforcing its retargeting specificity. Here, experimental
results are scarce and constrained to comparative analy-
sis of the infectivity of distinct oncolytic viruses. Thus,
for instance, Ketola et al. [1] compared the oncolysis in
five human osteosarcoma cell cultures infected with the
Semliki Forest virus V A7 − EGFP and the adenovirus
Ad5∆24. They found that the kinetics of adenovirus
infection was much slower than that of Semliki Forest
virus. High amounts of adenoviruses were required to
assure their spread throughout the cell culture and to
lyse all the osteosarcoma cells. Also, the authors demon-
strated differential efficacy of the Semliki Forest virus
against the human osteosarcoma cell lines. Virus spread-
ing was observed in four of five cell lines studied. In
particular, the cell lineage MG − 63 seemed to be rela-
tively resistant to the V A7 − EGFP infection. Clearly,
these results can be understood in terms of differences in
virus entry and replicative capacity as evidenced in our
model. By the way, some attempts to enhance the repli-
cation of oncolytic viruses have been performed since,
for instance, the burst size of a wild-type HSV is one
or two orders of magnitude greater than that of the en-
gineered vector hrR3. Alternatives include to place vi-
ral genes under the transcriptional control of tumor spe-
cific promoters [32] or mutate viruses to express genes
that overcome tumor cell pathways blocking viral pro-
tein synthesis [33]. Again, more attention need to be
paid to this approach. A greater activity is observed in
the field of virus spreading. Several vasoactive cytokines,
or physical treatments, such as radiation or heat, increase
tumor vascular permeability and blood flow, leading to
faster diffusion [34]. Such strategies can be particularly
relevant for systemic virus administration and to treat
tumors at the vascular stage, mainly compact tumors
exhibiting a fast growth as our results indicate. The
incorporation of lytic enzymes, such as hyaluronidase,
into a conditionally replicative adenovirus could also in-
crease diffusion rates [35]. Furthermore, agents that de-
crease the glycosaminoglycan concentration [36] or that
degrade interstitial collagen [37, 38] can improve trans-
port in tumors. For instance, tumor collagen can sig-
nificantly hinder diffusion, and it was shown [36] that
the matrix metalloproteinases−1 and −8 can modulate
the tumor matrix and improve the distribution of an on-
colytic virus throughout the tumor, without affect cell
proliferation or viral replication. In addition, a previous
work [39] showed that the matrix metalloproteinase−8
is antimetastatic, so it could be safely used to improve
the viral diffusion in tumors. Strategies that change the
tumor microenvironment are specially important to en-
hance the efficacy of virotherapy against avascular tu-
mors and occult dormant metastasis.
In summary, the outcomes of oncolytic virotherapy on
solid tumors were investigated through computer simula-
tions of a multiscale model for cancer growth. The model
combines macroscopic diffusion equations for the nutri-
ents and stochastic rules for the actions of individual cells
and viruses. Our simulations reveal that in immunosup-
pressed hosts the antitumor efficacy of a virus is deter-
mined primarily by its efficiency of entry, its replicative
capacity within the cancer cell, and its ability to spread
over the tissue. However, the balance between these vi-
ral traits depends on the tumor morphology. Indeed,
the virotherapy of papillary tumors based on oncolytic
viruses with small diffusivities is highly effective (success
probability ≥ 80%) even for small virus entry but high
replication capacity. Furthermore, the therapy fails if the
virus both spreads and lysis infected cells very rapidly. In
contrast, for compact tumors the therapy fails if vectors
characterized by small virus entry and slow intratumoral
spreading are used at safety MOIs. In turn, for dif-
fuse tumors an intermediate viral diffusivity maximizes
the therapeutic success. Thereby, the design of efficient
oncolytic viruses must take into account the dynamics
of tumor growth, which is fast for compact but slow for
papillary cancers. It is the tumor growth that sets up the
optimal traits for oncolytic viruses. Those traits do not
necessarily include high diffusivity and cytolysis, which
are naively assumed as necessary conditions to amplify
the therapeutic inoculum in situ and promote a fast viral
spreading throughout the affected tissue.
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7FIG. 1. (Color online) Schematic illustration of the
mathematical approach. The model consider normal cells,
tumor cells, and oncolytic viruses. Uninfected cancer cells can
replicate by mitosis or die due to starvation (lack of nutrients)
or move or become infected, a quiescent state in which the cel-
lular machinary is slaved to promote viruses replication. Cell
actions are stochastically governed by probabilities Pdiv , Pdel,
Pmov and Pinf dependent on the nutrient and virus concen-
trations per cancer cell. Infected cancer cells die by lysis with
probability Plysis. After mitosis, the new tumor cell can ei-
ther pile up (loss of contact inhibition) at the site of its parent
cell or invade randomly one of their normal or necrotic nearest
neighbor cell, if there exists any. Nutrients are modelled as
continuous concentrations which evolve in space (tissue) and
time according reaction-diffusion equations. Essentially, nu-
trients diffuse from the capillary vessel through the tissue and
are uptaken by normal and tumor cells at distinct rates. Free
viruses perform Brownian motions (lattice diffusion) and are
cleared at a rate γv. The source of new viruses are infected
cancer cells which release v0 new viruses after undergoing ly-
sis. The virus clearance rate represents the simplest way to
introduce viral loss due mainly to the innate and adaptive
immune response mediated by antibodies, CD8 T cells, inter-
ferons and other cytokines or inherent viral instability.
FIG. 2. Simulated morphologies for avascular tumor
growth. (A) Solid or compact tumors grow exponentially
fast under weak competition for nutrients and reduced cell
motility. (B) Diffuse or disconnected tumors are characterized
by a moderate level of nutrient competition and a high cell
motility. (C) Papillary patterns emerge under strong nutrient
competition and low cell motility, resulting in a very slow
growth. The parameters used are listed in Table 1. All tumor
patterns shown have 104 cells. The capillary is at the bottom
of the frames.
FIG. 3. (Color online) Temporal evolution of uninfected
cancer cells (solid black line) and free viruses popu-
lations (dashed blue line) in a diffuse tumor. A sin-
gle intratumoral virus load was administered when the tumor
had N0 = 5, 000 cells. Notice that three different behaviors
were obtained using exactly the same fixed set of parameters
and initial conditions (MOI = 1, bs = 100, k = 1, q = 25,
Tl = 16). These different behaviors emerge from stochasticity.
The parameters used are listed in Table 1.
FIG. 4. Papillary tumor erradication probability for
distinct virus diffusivities q and time for lysis Tl. Two
viral burst sizes (A) bs = 10 and (B) bs = 100 are shown.
The values γv = 0.03, θinf = 0.01, MOI = k = 1, and
N0 = 10
4 are fixed. The probabilities were evaluated from 50
independent samples.
FIG. 5. Solid tumor erradication probability as a func-
tion of the parameters q and Tl. (a) MOI = 1 and viral
entry k = 5, and (b) MOI = k = 1.5. The viral burst
size is bs = 100 and the values γv = 0.03, θinf = 0.01, and
N0 = 5, 000 are fixed. The probabilities were evaluated from
50 independent samples for each pair (q, Tl).
FIG. 6. Diffuse tumor erradication probability as a
function of the parameters q and Tl. A viral burst size
bs = 100 was used. The values γv = 0.03, θinf = 0.01,
MOI = 1, k = 1 and N0 = 10, 000 are fixed.
Appendix A: Simulation protocol
The simulations were implemented as follows. At each
time step, eq. (1) is numerically solved in the stationary
state (∂φ/∂t = 0) through relaxation methods. Also, a
fraction of the free viruses present in every site is cleared,
and each remaining virus performs an independent ran-
dom walk with q steps. Provided the nutrient concentra-
tion and viral load at any lattice site, Nc(t) cancer cells
are sequentially selected at random with equal probabil-
ity. (Here, Nc(t) is the total number of tumor cells, unin-
fected or infected, at the time t.) For each one of them, a
tentative action (division, death, migration or infection
for an uninfected cancer cell, and lysis for an infected
one) is randomly chosen with equal probability. The se-
lected cell action will be implemented or not according to
the corresponding local probabilities determined by eqs.
(2), (3), (4), (5) and (7), and the time is incremented by
∆t = 1/Nc(t). If the carried action is the infection of the
selected cell, an integer random number nv distributed
as a Poissonian is generated and compared with the local
virus population σv. If σv ≥ nv, nv viruses invade the
uninfected cancer cell, decreasing σv by nv. Otherwise,
this process will be repeated until generates a nv ≤ σv.
In turn, if the carried action is the lysis of the selected
cell, v0 new viruses are introduced at the site of the lysed
cell. At the end of this sequence of Nc(t) updates, a new
time step starts and the entire procedure (solution of the
reaction-diffusion equations, virus clearance and spread-
ing, and cell dynamics) is iterated. It is worthy to notice
that a particular cell can possibly perform more than one
action in a certain time step, but in average every cancer
cell will perform the same number of actions. Also, the
increment time ∆t assures that, in average, each cancer
cell present in a given time has a chance to perform an
action during that time step. The simulations stop if
any tumor cell reaches the capillary vessel or the tissue
border or if the tumor is erradicated (Nc = 0).
Appendix B: Parameter estimates
In all simulations, the tissue is represented by a square
lattice of linear size L = 500 and lattice constant ∆ = 10
µm, corresponding to a tissue section of about 25mm2.
Assuming a DNA synthesis phase of the cell cycle of
about 11 h [40], one time step in the simulations cor-
responds to about 4 − 5 h. The parameters θdiv = 0.3
and λ2 = 10 were fixed. In order to generate compact,
papillary, and disconnected tumor growth patterns dis-
tinct values of the parameters θdel, θmov, λ1, and α were
used, as listed in Table 1. The parameters γv and θinf ,
8characterizing the oncolytic virus, were also fixed (Table
1). The key parameters controlling virus diffusion q, en-
try k, replication bs, its time for triggering cell lysis Tl
and MOI specifying the virotherapy, were varied. The
therapy begins when the tumors have either N0 = 5000
or 10, 000 cells.
The value fixed for γv, controlling viral clearance, is
the same used in Ref. [8] and corresponds to a virus
with a long residence time in the tissue (low clearance
rate). In turn, the value θinf = 0.01 corresponds to a
highly infective oncolytic virus (Pinf = 90%). Both of
than are rather arbitrary, but for comparision, 70% of the
hrR3 viruses successfully invade uninfected glioma cells
[7]. The other viral parameters were varied in ranges
biologically reasonable. Indeed, bs ranged in the inter-
val [10, 100] as experimentally observed for the burst size
of the oncolytic virus hrR3 [7]. The MOI also varied
within ranges used in virotherapy trials [26]. For com-
parision, viral doses ranging from about 107 pfu (MOI
∼ 0.08) to 109 pfu (MOI ∼ 8) were used in experimental
tests [26]. The characteristic time for lysis Tl was var-
ied as in ref. [8]. Assuming a simulational time step of
4 hours, Tl ranged from 8 hours to 5 days. For com-
parision, the mean life time of glioma cells infected by
hrR3 is ∼ 18 hours [7] and the lytic cycle of the Aden-
ovirus Ad2 is 32− 36 hours. So, the simulations assume
viruses whichare 4 times faster to 4 times slower than the
Ad2. The values considered for the virus entry k lead,
in average, to cell infections by few virus simultaneously.
Unfortunatelly, we can not found direct measures or es-
timates fo k in the literature. Finally, q (the number
of steps in a viral random walk), a measure of the viral
spreading capacity, was estimated as follows. Since in a
random walk < r2 >= Dt or < r2 >= q∆2, where D is
the diffusion constant, t is the diffusion time and ∆ the
lenght step, the virus diffusivity can be determined from
q. Assuming ∆ ∼ 10µm (lattice constant=linear cell
size) and t = 4h, one finds Dmin = 2.5 × 10
−5mm2h−1
for q = 1 and Dmax = 6.25 × 10
−4mm2h−1for q = 25.
These are the limit values used for the virus diffusiv-
ity in the simulations. Taking as a reference value
D = 1.8 × 10−4mm2h−1, the diffusivity of the HSV in
tumors with high collagen content [41], Dmin is ∼ 14
times smaller and Dmax is ∼ 3.5 times greater than this
reference.
Appendix C
Here, additional results concerning the progress curves
of virus and uninfected cancer cells for compact and pap-
illary tumors are shown in figures 7 and 8, respectively.
Also, the effect of the viral burst size for oncolytic agents
characterized by moderate (k = 2) and high (k = 5) virus
entry are exhibited in figures 9 and 10, respectively.
FIG. 7. (Color online) Progress curves - Nc (solid black
line) and vfree (dashed blue line) - for compact tu-
mors. The values q = 4, Tl = 16, bs = 100 and N0 = 5, 000
were used in all figures. In the case of tumor eradication,
MOI = 5 and k = 5 were used. Coexistence of tumor cells
and viruses is observed at MOI = 1 and k = 1. At last, virus
erradication occurs at MOI = 0.01 and k = 0.01.
FIG. 8. (Color online) Progress curves - Nc (solid black
line) and vfree (dashed blue line) - for papillary tu-
mors. The values q = 25, Tl = 4, bs = 100 and k = 1 for the
virus and MOI = 1 and N0 = 5, 000 for the virotherapy were
used.
FIG. 9. The success probability of a virotherapy ap-
plied to compact or solid tumors using MOI = k = 2.
At the left bs = 10 and at the right bs = 100 were used.
N0 = 5, 000 was fixed for the virotherapy. As can be no-
ticed, an unexpected coupling between Tl and bs is observed.
Indeed, for a large viral burst size bs = 100 the success prob-
ability is practically independent on Tl. However, for a small
value (bs = 10) this probability decreases with increasing Tl
for q < 10 (small viral spreading) but increases with Tl at
larger q values. It seems that at a high diffusivity even a
virus with a low replicative capacity can sustain successive
waves of infection by lysing the scattered cells that survives
the previous round of infection.
FIG. 10. The success probability of a virotherapy
applied to solid tumors using MOI = 1, k = 5 and
N0 = 5, 000. At the left bs = 10 and at the right bs = 100.
Notice that the therapeutic success decreases only for virus
with very low spreading, particularly when its replicative ca-
pacity is low too.
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TABLE I. Parameter values used in the simulations.
Tumor Parameter Values Description
morfology
θdiv 0.3 (fixed) Controls the probability
of cancer cell division.
λ2 10 (fixed) Controls the competition
for NE nutrients.
θdel 0.03 Controls the probability
of cancer cell death.
Compact θmov 5 Controls the probability
or of cancer cell migration.
solid λ1 25 Controls the competition
for E nutrients.
α 0.02 Dimensionless nutrient
uptake rate for normal cells.
Papillary θdel 0.01
or θmov 5
ramified λ1 200
α 0.06
Disconnected θdel 0.01
or θmov 0.001
diffuse λ1 50
α 0.06
Viral traits
θinf 0.01 (fixed) Determines the chance of
virus infection (infectivity).
γv 0.01 (fixed) Virus clearance rate
on the tissue.
A 0.5 (fixed) Controls the number of virus
released after cell lysis
MOI 1, 1.5, 5 Initial viral load
(MOI) administered.
k 1, 1.5, 5 Number of virus entering
a cell at infection
bs 10, 50, 100 Maximum number of viruses
released after cell lysis.
q 1, 4, 9, 16, 25 Number of random steps per-
formed by a virus per MCS.
Tl 2, 4, 8, 16, 32 Characteristic time
for cell lysis.
Abbreviations: NE and E, non-essential and essential for DNA
replication and mitosis, respectively; MOI, multiplicity of
infection; MCS, Monte Carlo or simulation time step.










